Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and Stomach Neoplasms

erlotinib hydrochloride has been researched along with Stomach Neoplasms in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's6 (54.55)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Chen, M; Fan, Z; Feng, H; Hou, J; Li, F; Li, J; Li, YY; Liu, B; Pan, T; Sang, Q; Su, L; Wu, X; Yan, C; Yu, B; Yu, J; Yu, Y; Zang, M; Zhu, Z1
Ito, A; Ito, S; Kaneda, N; Kodera, Y; Nakanishi, H; Sakao, Y; Yatabe, Y; Yoshimura, M1
Hattori, S; Kage, M; Kan, H; Kawahara, A; Kuwano, M; Murakami, Y; Ono, M; Shibata, T; Ureshino, H; Watari, K1
Atoyan, R; Cai, X; Lai, CJ; Ma, AW; Pursell, NW; Samson, ME; Savagner, P; Selmi, A; Voi, M; Wang, J; Xu, W1
Feng, R; Yang, S1
Ding, LY; Jiang, ZL; Liu, KJ; Wu, HY; Wu, SX1
Anghel, A; Ayala, R; Desai, AJ; Fejzo, MS; Finn, RS; Hecht, JR; Luo, T; Safran, B; Slamon, DJ; Wainberg, ZA1
Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M1
Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H1
Abbruzzese, JL; Baker, AF; Benedetti, JK; Blanke, CD; Dragovich, T; Fenoglio-Preiser, CM; Hackett, CB; McCoy, S; Urba, SG; Wang, J; Zaner, KS1
Personeni, N1

Reviews

1 review(s) available for erlotinib hydrochloride and Stomach Neoplasms

ArticleYear
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
    World journal of gastroenterology, 2006, Jun-07, Volume: 12, Issue:21

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab

2006

Trials

1 trial(s) available for erlotinib hydrochloride and Stomach Neoplasms

ArticleYear
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30

    Topics: Biomarkers, Tumor; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome

2006

Other Studies

9 other study(ies) available for erlotinib hydrochloride and Stomach Neoplasms

ArticleYear
BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023, Volume: 10, Issue:34

    Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phospholipase C gamma; Stomach Neoplasms

2023
Dynamics of Circulating Tumor Cells Early After Targeting Therapy to Human
    Anticancer research, 2019, Volume: 39, Issue:9

    Topics: Animals; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Heterografts; Humans; Immunohistochemistry; Mice; Mutation; Neoplastic Cells, Circulating; Receptor, ErbB-2; Stomach Neoplasms

2019
Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Y-Box-Binding Protein 1

2013
Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:6

    Topics: Cadherins; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms

2013
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.
    The Journal of international medical research, 2016, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Erlotinib Hydrochloride; Focal Adhesion Protein-Tyrosine Kinases; Humans; Neoplasm Invasiveness; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Transfection

2016
Targeted therapy of multiple liver metastases after resected solitary gastric metastasis and primary pulmonary adenocarcinoma.
    Oncotarget, 2016, Dec-27, Volume: 7, Issue:52

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gastrectomy; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Positron Emission Tomography Computed Tomography; Stomach Neoplasms

2016
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoprecipitation; In Situ Hybridization, Fluorescence; Lapatinib; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Trastuzumab; Xenograft Model Antitumor Assays

2010
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
    Lung cancer (Amsterdam, Netherlands), 2005, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms

2005
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7

    Topics: ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Stomach Neoplasms; Treatment Outcome

2007